Sodium Lactate 0.167 Molar In Plastic Container

(Sodium Lactate)

Phase 2Small molecule

Sodium Lactate 0.167 Molar In Plastic Container is one of 122 small molecule programs targeting Hypoglycemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

121

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

Cardiac ArrestRecruiting

SepsisRecruiting

Major Depressive DisorderNot yet recruiting

HypoglycemiaPreclinical

Active, not recruiting

Cardiac ArrestPhase 2

Recruiting

SepsisPhase 2

Recruiting

Major Depressive DisorderPhase 2

Not yet recruiting

Competition

Competitive Landscape

120 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Ketalar

Boehringer Ingelheim

Phase 3

3 3

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 4

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 5

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 6

Psilocybin

COMPASS Pathways

Phase 3

11 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 8

Aticaprant

Johnson & Johnson

Phase 3

4 9

Selective Serotonin Reuptake Inhibitor

Johnson & Johnson

Phase 3

2 10

CYB003

CCybin IRL Limited

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Sepsis

NCT06634069

Q1 2028

Phase 2Not yet recruiting

Major Depressive Disorder

NCT06168175

Q2 2028

Phase 2Recruiting

Cardiac Arrest

NCT05004610

Q3 2038

Phase 2Not yet recruiting

TBI

NCT06701760

Clinical

Trials by Indication[1]

Hypoglycemia2 trials

The Effect Lactate Administration on Cerebral Blood Flow During Hypoglycemia

Unknown status·RRadboud University Medical Center·N/A·NCT03730909·10 enrolled

The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia

Completed·RRadboud University Medical Center·N/A·NCT03286816·19 enrolled

Cardiac Arrest1 trial

Hypertonic Lactate After Cardiac Arrest

Recruiting·EErasme University Hospital·Phase 2·NCT05004610·125 enrolled

Sepsis1 trial

Study SOLACE SEPSIS

Recruiting·UUniversity Hospital Pilsen·Phase 2·NCT06634069·40 enrolled

Brain Injury1 trial

Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)

Withdrawn·UUniversity of California, Los Angeles·Phase 2·NCT02776488

TBI1 trial

Sodium Lactate in Severe TBI

Not yet recruiting·UUniversity of California, Los Angeles·Phase 2·NCT06701760·264 enrolled

3 more indications

AIN1 trial

Sodium Lactate and Brain Relaxation (LSD)

Completed·—·Phase 3·NCT04488874·50 enrolled

Major Depressive Disorder1 trial

Feasibility of Conducting a Clinical Trial Assessing Efficacy of Lactate as Adjunctive Therapy in Patients With Major Depressive Disorder

Not yet recruiting·—·Phase 2·NCT06168175·46 enrolled

Unspecified1 trial

Lactate in the Gut

Completed·UUniversity of Aarhus·N/A·NCT04299815·10 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

NDA NDA018186

Jan 1, 1982

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

NDA NDA016692

Jan 1, 1982

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

NDA NDA018249

Sep 5, 1984

SODIUM LACTATE IN PLASTIC CONTAINER

NDA NDA018947

Apr 21, 1992

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

NDA NDA020004

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Sodium Lactate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Lactate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Lactate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020004). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Sodium Lactate 0.167 Molar In Plastic Container

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2028

Q3 2038

Trials by Indication[1]

Hypoglycemia2 trials

Cardiac Arrest1 trial

Sepsis1 trial

Brain Injury1 trial

TBI1 trial

AIN1 trial

Major Depressive Disorder1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News